Skip links

Archive

New Funding Boosts URMC Biotech Start-Up for Neurological Disorders

New Funding Boosts URMC Biotech Start-Up for Neurological Disorders

in

Oscine Therapeutics, a new biotechnology company based on discoveries made and developed at the University of Rochester Medical Center (URMC) has received a significant multi-year investment to support both research and development of cell-based therapies for neurological disorders. The funding represents the largest-ever investment in

Handy Gelbard Authors STAT News Piece Touting Multi-Target Drugs

Handy Gelbard Authors STAT News Piece Touting Multi-Target Drugs

in

Precision medicine is saving lives, but Harris A. (Handy) Gelbard, director of Center for Neurotherapeutics Discovery at URMC, believes we’re overlooking another class of extremely important treatment candidates: multi-target drugs. In STAT News, he shares his views on why U.S.-based pharmaceutical companies should pay closer attention